Table 4.
Identification of prognostic-related clinical factors and clinical independence using univariate and multivariate Cox regression analyses in the TCGA training set, TCGA test set, GSE19234, and GSE65904.
| Variables | Univariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | p value | HR | 95% CI of HR | p value | |
| TCGA training datasets | ||||||
| 6-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 2.81 | 1.91-4.14 | 1.63E-07 | 1.87 | 1.11-3.14 | 0.018 |
| Age | 1.03 | 1.01-1.04 | 1.76E-05 | 1.02 | 1.001-1.03 | 0.03736 |
| Gender female | 1 (reference) | |||||
| Gender male | 1.14 | 0.77-1.67 | 0.51 | 0.98 | 0.61-1.58 | 0.941573 |
| Pathologic T1 | 1 (reference) | 1 (reference) | ||||
| Pathologic T2 | 2.24 | 0.90-5.53 | 0.08 | 1.88 | 0.68-5.21 | 0.227 |
| Pathologic T3 | 2.99 | 1.22-7.3 | 0.02 | 5.52 | 1.50-20.24 | 0.01 |
| Pathologic T4 | 5.75 | 2.36-13.96 | 1.10E-04 | 11.88 | 3.31-42.52 | 1.43E-04 |
| Pathologic N0 | 1 (reference) | 1 (reference) | ||||
| Pathologic N1 | 1.49 | 0.85-2.61 | 0.163 | 2.58 | 0.31-20.90 | 0.374 |
| Pathologic N2 | 1.94 | 1.06-3.55 | 0.03 | 2.6 | 0.31-21.56 | 0.375 |
| Pathologic N3 | 2.68 | 1.53-4.67 | 5.30E-04 | 7.35 | 0.88-60.98 | 0.065 |
| Pathologic M0 | 1 (reference) | 1 (reference) | ||||
| Pathologic M1 | 1.66 | 0.83-3.28 | 0.151 | 1.26 | 0.42-3.74 | 0.67 |
| Tumor stage I | 1 (reference) | 1 (reference) | ||||
| Tumor stage II | 1.64 | 0.92-2.89 | 0.089 | 0.28 | 0.092-0.82 | 0.022 |
| Tumor stage III/IV | 2.25 | 1.32-3.79 | 0.002 | 0.22 | 0.024-2.0024 | 0.18 |
| Validation cohort, TCGA test datasets, GSE19234, and GSE65904 | ||||||
| TCGA test datasets | ||||||
| 6-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 1.54 | 1.04-2.26 | 0.029 | 1.41 | 0.86-2.29 | 0.166 |
| Age | 1.02 | 1.007-1.034 | 0.003 | 1.01 | 0.99-1.02 | 0.223 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 1.28 | 0.83-1.97 | 0.26 | 1.23 | 0.70-2.16 | 0.454 |
| Pathologic T1 | 1 (reference) | 1 (reference) | ||||
| Pathologic T2 | 0.98 | 0.42-2.26 | 0.957 | 1.35 | 0.48-3.75 | 0.563 |
| Pathologic T3 | 1.4 | 0.62-3.12 | 0.409 | 1.25 | 0.33-4.69 | 0.737 |
| Pathologic T4 | 2.47 | 1.13-5.36 | 0.023 | 2.3 | 0.62-8.45 | 0.21 |
| Pathologic N0 | 1 (reference) | 1 (reference) | ||||
| Pathologic N1 | 1.46 | 0.85-2.49 | 0.168 | 2.12 | 0.57-7.94 | 0.261 |
| Pathologic N2 | 1.11 | 0.54-2.24 | 0.78 | 2.29 | 0.57-9.12 | 0.237 |
| Pathologic N3 | 3 | 1.47-6.09 | 0.002 | 5.86 | 1.4-24.53 | 0.015 |
| Pathologic M0 | 1 (reference) | 1 (reference) | ||||
| Pathologic M1 | 4.35 | 1.01-18.62 | 0.047 | 5.307 | 0.54-51.81 | 0.151 |
| Tumor stage I | 1 (reference) | 1 (reference) | ||||
| Tumor stage II | 1.51 | 0.83-2.73 | 0.172 | 1.14 | 0.37-3.5 | 0.813 |
| Tumor stage III/IV | 1.86 | 1.06-3.28 | 0.03 | 0.88 | 0.18-4.21 | 0.882 |
| GSE19234 | ||||||
| 6-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 3.22 | 1.18-8.76 | 0.022 | 3.34 | 1.2-9.3 | 0.021 |
| Age | 1.01 | 0.98-1.02 | 0.579 | 1 | 0.97-1.023 | 1 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 0.76 | 0.33-1.75 | 0.526 | 0.93 | 0.4-2.15 | 0.868 |
| Tumor stage III | 1 (reference) | 1 (reference) | ||||
| Tumor stage IV | 4.03 | 1.43-11.38 | 0.008 | 4.29 | 1.46-12.56 | 0.008 |
| GSE65904 | ||||||
| 6-gene risk score | ||||||
| Low-risk group | 1 (reference) | 1 (reference) | ||||
| High-risk group | 1.53 | 1.036-2.265 | 0.032 | 1.492 | 1.002-2.220 | 0.0488 |
| Age | 0.998 | 0.984-1.012 | 0.796 | 1.001 | 0.987-1.015 | 0.927 |
| Gender female | 1 (reference) | 1 (reference) | ||||
| Gender male | 0.748 | 0.496-1.13 | 0.169 | 0.788 | 0.522-1.192 | 0.259 |